세계의 심상성 천포창 시장 - 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 유통 채널별, 지역별 부문 예측(2025-2033년)

Pemphigus Vulgaris Market Summary

The global pemphigus vulgaris market size was estimated at USD 481.3 million in 2024 and is projected to reach USD 975.2 million by 2033, growing at a CAGR of 8.2% from 2025 to 2033. Improved diagnostics & early detection, advancements in treatment modalities, and increasing R&D investments drive market growth.

Pemphigus vulgaris is a rare, severe autoimmune blistering disease primarily affecting the skin and mucous membranes. It accounts for approximately 70% of all pemphigus cases globally. Reported incidence varies globally by geography and ethnicity, ranging from 0.5 to 50 new cases per million people yearly.

Governments and foundations worldwide have initiated several programs to support individuals suffering from PV. For instance, in December 2023, in the U.S., the PAN Foundation, in partnership with the International Pemphigus & Pemphigoid Foundation (IPPF), offered financial assistance to PV patients. Eligible individuals are provided up to USD 6,600 annually to cover expenses and support services for patients & their caregivers.

Global Pemphigus Vulgaris Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pemphigus vulgaris market report based on therapy type, distribution channel, and region:

• Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
• Anti-CD20 monoclonal antibodies (rituximab)
• Systemic corticosteroids
• Conventional steroid-sparing immunosuppressants
• Intravenous immunoglobulin (IVIG) - adjunct
• Topical therapies
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy Type
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pemphigus Vulgaris Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Pemphigus Vulgaris Market: Therapy Type Business Analysis

• 4.1. Therapy Type Market Share, 2024 & 2033
• 4.2. Therapy Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
• 4.4. Anti-CD20 monoclonal antibodies (rituximab)
  • 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.5. Systemic corticosteroids
  • 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.6. Conventional steroid-sparing immunosuppressants
  • 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.7. Intravenous immunoglobulin (IVIG) - adjunct
  • 4.7.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.8. Topical therapies
  • 4.8.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pemphigus Vulgaris Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pemphigus Vulgaris Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 6.4. North America
  • 6.4.1. North America Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Reimbursement Framework
    • 6.4.2.4. U.S. Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Reimbursement Framework
    • 6.4.3.4. U.S. Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Reimbursement Framework
    • 6.4.4.4. Mexico Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Reimbursement Framework
    • 6.5.2.4. UK Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Reimbursement Framework
    • 6.5.3.4. Germany Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Reimbursement Framework
    • 6.5.4.4. France Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Reimbursement Framework
    • 6.5.5.4. Italy Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Reimbursement Framework
    • 6.5.6.4. Spain Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Reimbursement Framework
    • 6.5.7.4. Denmark Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Reimbursement Framework
    • 6.5.8.4. Sweden Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Reimbursement Framework
    • 6.5.9.4. Norway Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Reimbursement Framework
    • 6.6.2.4. Japan Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Reimbursement Framework
    • 6.6.3.4. China Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Reimbursement Framework
    • 6.6.4.4. India Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Reimbursement Framework
    • 6.6.5.4. Australia Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Reimbursement Framework
    • 6.6.6.4. South Korea Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Reimbursement Framework
    • 6.6.7.4. Thailand Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Reimbursement Framework
    • 6.7.2.4. Brazil Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Reimbursement Framework
    • 6.7.3.4. Argentina Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Pemphigus Vulgaris Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Reimbursement Framework
    • 6.8.2.4. South Africa Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Reimbursement Framework
    • 6.8.3.4. Saudi Arabia Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Reimbursement Framework
    • 6.8.4.4. UAE Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Reimbursement Framework
    • 6.8.5.4. Kuwait Pemphigus Vulgaris Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Genentech, Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. CELLTRION INC.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amgen Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Zenyaku Kogyo Co.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives